107
Participants
Start Date
August 1, 2025
Primary Completion Date
March 31, 2029
Study Completion Date
March 31, 2031
Visugromab
Participants receive Visugromab (recommended dose) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
Matching placebo for visugromab
Participants receive Matching Placebo intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
Pembrolizumab 200 mg Q3W
Participants receive Pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments after visugromab infusion.
Pemetrexed 500 mg/m^2
Participants receive Pemetrexed 500 mg/m\^2 IV on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
Carboplatin AUC 5
Participants receive Carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) on Day 1 of each 21-day cycle for four cycles.
ACTIVE_NOT_RECRUITING
Fribourg Cantonal Hospital, Fribourg
ACTIVE_NOT_RECRUITING
University Hospital Basel, Basel
ACTIVE_NOT_RECRUITING
Cantonal Hospital Saint Gallen, Clinic of Oncology and Hematology, Sankt Gallen
RECRUITING
Großhansdorf Hospital - Clinical Center for Pulmonology and Thoracic Surgery, Department of Thoracic Oncology, Großhansdorf
NOT_YET_RECRUITING
University Hospital of Jaen, Jaén
NOT_YET_RECRUITING
University Hospital Lucus Augusti (HULA), Lugo
NOT_YET_RECRUITING
Duke University Medical Center, Durham
RECRUITING
Regional University Hospital of Malaga, Málaga
NOT_YET_RECRUITING
Evangelical Hospital Bethel, Clinic for Internal Medicine, Hematology/Oncology, Palliative Medicine Johannesstift, Bielefeld
RECRUITING
Clinics Essen-Mitte, Essen
NOT_YET_RECRUITING
USC Norris Comprehensive Cancer Center, Los Angeles
NOT_YET_RECRUITING
University of Alabama at Birmingham, Birmingham
NOT_YET_RECRUITING
Yale Cancer Center, New Haven
CatalYm GmbH
INDUSTRY